The estimated Net Worth of Brendan P.Eckelman Living T... is at least $39.8 Milione dollars as of 1 March 2023. Brendan T owns over 40,000 units of Inhibrx stock worth over $30,533,295 and over the last 4 years Brendan sold INBX stock worth over $9,232,856.
Brendan has made over 12 trades of the Inhibrx stock since 2021, according to the Form 4 filled with the SEC. Most recently Brendan sold 40,000 units of INBX stock worth $968,400 on 1 March 2023.
The largest trade Brendan's ever made was selling 40,000 units of Inhibrx stock on 1 March 2023 worth over $968,400. On average, Brendan trades about 28,171 units every 53 days since 2021. As of 1 March 2023 Brendan still owns at least 2,035,553 units of Inhibrx stock.
You can see the complete history of Brendan T stock trades at the bottom of the page.
Over the last 4 years, insiders at Inhibrx have traded over $27,711,393 worth of Inhibrx stock and bought 2,717,119 units worth $64,845,764 . The most active insiders traders include Global Investors Lp Viking ..., Capital Management, L.P.Kol... e Global Investors Lp Viking .... On average, Inhibrx executives and independent directors trade stock every 42 days with the average trade being worth of $1,598,400. The most recent stock trade was executed by Mark Lappe on 6 September 2024, trading 44,000 units of INBX stock currently worth $671,000.
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Inhibrx executives and other stock owners filed with the SEC include: